샘플 요청 목록

 카트 문의
시장보고서
상품코드
1944412

괴사성 근막염 시장 : 진단별, 증상별, 약물별, 종류별, 최종 용도별, 치료법별, 위험인자별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

Necrotizing Fasciitis Market, By Diagnosis, By Symptoms, By Drug, By Type, By End-Use, By Treatment, By Risk Factors, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 332 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

괴사성 근막염 시장 규모는 2024년에 11억 121만 달러로 평가되었으며, 2025년부터 2032년까지 CAGR 8.09%로 확대될 전망입니다.

괴사성 근막염 시장에는 드물지만 빠르게 진행되는 연조직 감염을 치료하기 위한 진단 도구, 항균 요법, 외과적 개입 및 지지요법 솔루션이 포함됩니다. 고령화, 만성질환, 외상, 재난 후 감염과 관련된 발병률 증가는 즉각적인 의료 대응을 필요로 하며 시장 성장을 촉진하고 있습니다. 신속한 진단, 첨단 영상 진단, 적극적인 병용요법은 조기발견과 생존율 향상을 위한 주요 시장 트렌드입니다. 그러나 진단의 지연, 높은 치료비, 낮은 질환 인지도가 여전히 큰 장벽으로 작용하고 있습니다. 이러한 어려움에도 불구하고, 신속한 현장 진단, 새로운 항균제, 개선된 집중 치료 프로토콜 등의 발전으로 고위험 임상 환경에서 조기 개입과 환자 결과 개선이 가능해지면서 새로운 기회가 창출되고 있습니다.

괴사성 근막염의 시장 역학

의료비 지출 증가가 시장 성장을 견인

의료비 증가는 향후 몇 년 동안 괴사성 근막염 시장의 성장을 크게 뒷받침할 것으로 예상됩니다. 의료비에는 정부, 민간 보험사, 고용주, 개인이 의료 서비스, 치료, 의약품 및 관련 의료 활동에 지출하는 총 지출이 포함됩니다. 의료비 지출 증가는 지속적인 치료와 고도의 치료적 개입을 필요로 하는 만성질환의 부담 증가에 기인합니다. 지출 수준 향상은 조기 진단 기술, 혁신적인 치료 옵션, 전문 집중 치료 서비스에 대한 접근성을 향상시켜 괴사성 근막염 관리를 강화할 수 있습니다.

예를 들어, 2025년 6월 미국 메디케어-메디케이드 서비스센터가 발표한 자료에 따르면, 2023년 국내 의료비는 7.5% 증가하여 4조 9,000억 달러(1인당 1만 4,570달러)로 GDP의 17.6%를 차지합니다. 메디케어 지출은 8.1% 증가한 1조298억 달러로 국내 총 의료비의 21%를 차지했습니다. 그 결과, 확대되는 의료 예산이 질병 관리 개선에 기여하며 시장 성장을 견인하고 있습니다.

괴사성 근막염 시장 : 세분화 분석

세계 괴사성 근막염 시장은 진단, 증상, 약물, 유형, 최종 용도, 치료법, 위험 요소, 지역별로 세분화됩니다.

유형 II(단일 미생물성) 부문은 세계 시장에서 상당한 비중을 차지할 것으로 예상됩니다. 이러한 증가는 I형과 III형 중 가장 흔하고 모든 연령층에 영향을 미치는 II형 괴사성 근막염의 전 세계 감염 확산에 기인하는 것으로 보입니다. 이러한 상황은 주요 기업들이 항생제 공급을 늘리도록 유도할 것으로 예상되며, 향후 몇 년 동안 이 부문의 성장을 견인할 것으로 보입니다. 2024년 8월 DermNet에 게재된 기사에 따르면, 육식성 질환으로도 알려진 II형 괴사성 근막염은 건강한 사람을 포함한 모든 연령층에 영향을 미친다고 합니다.

약제별로는 반코마이신이 향후 몇 년 동안 큰 시장 점유율을 차지할 것으로 예상됩니다. 이 부문의 확대는 메티실린 내성 황색포도상구균(MRSA)이 의심되는 경우 다른 약제와 함께 반코마이신이 우선적으로 선택되는 것에 기인합니다. 이에 따라 향후 몇 년 동안 반코마이신에 대한 수요가 증가할 것으로 예상됩니다. 예를 들어, WHO 필수 의약품 선정 및 사용 전문가 위원회는 2021년 반코마이신이 다른 약물과 병용할 경우 MRSA 내성에 효과적이라고 밝혔습니다.

괴사성 근막염 시장 - 지역별 분석

2025년에도 북미는 괴사성 근막염(PPA) 시장의 수익과 보급을 주도하는 주요 지역 중 하나가 될 것으로 예상됩니다. 이는 이 지역의 괴사성 근막염 진단 건수 증가가 성장에 기여하고 있기 때문입니다. 이러한 상황이 괴사성 근막염 치료에 대한 수요를 촉진하고 있으며, 시장 성장의 가속화가 예상됩니다. 예를 들어, WebMD LLC가 2023년 11월에 발표한 기사에 따르면, 미국에서는 매년 약 700건에서 1,150건의 괴사성 근막염이 진단되고 있다고 합니다.

미국 괴사성 근막염 시장 - 국가별 분석

미국 괴사성 근막염 시장은 첨단 임상 연구 인프라와 현대 진단 기술에 대한 광범위한 접근성을 바탕으로 질병의 조기 발견과 효과적인 관리를 뒷받침하고 있습니다. 또한, 존슨앤드존슨과 화이자를 포함한 주요 의료 서비스 제공자 및 제약사들은 항균 치료 및 지지요법 솔루션 개발에 많은 투자를 하고 있습니다. 감염병 관리 프로토콜 강화와 희귀질환 연구에 대한 자금 지원 확대에 초점을 맞춘 정부 정책은 시장 성장을 더욱 촉진하고 있습니다. 예를 들어, 노바베이 파마슈티컬스는 상처 치료 분야에 적극적으로 참여하고 있으며, 차아염소산 기반 솔루션 '뉴트로페이즈'는 괴사성 근막염을 포함한 심각한 감염성 질환의 상처 세척에 활용되고 있습니다. 이는 미국이 선진적인 치료 및 관리 전략을 매우 중요하게 여긴다는 것을 보여줍니다.

목차

제1장 괴사성 근막염 시장 개요

제2장 주요 요약

제3장 괴사성 근막염 주요 시장 동향

제4장 괴사성 근막염 산업 조사

제5장 괴사성 근막염 시장 : 높아지는 지정학적 긴장의 영향

제6장 괴사성 근막염 시장 구도

제7장 괴사성 근막염 시장 : 진단별

제8장 괴사성 근막염 시장 : 증상별

제9장 괴사성 근막염 시장 : 약물별

제10장 괴사성 근막염 시장 : 종류별

제11장 괴사성 근막염 시장 : 최종 용도별

제12장 괴사성 근막염 시장 : 치료법별

제13장 괴사성 근막염 시장 : 위험인자별

제14장 괴사성 근막염 시장 : 지역별

제15장 주요 벤더 분석 : 괴사성 근막염 업계

제16장 AnalystView의 전방위적 분석

KSM 26.03.13

Necrotizing Fasciitis Market size was valued at US$ 1,101.21 Million in 2024, expanding at a CAGR of 8.09% from 2025 to 2032.

The necrotizing fasciitis market includes diagnostic tools, antimicrobial therapies, surgical interventions, and supportive care solutions for treating this rare but rapidly progressing soft-tissue infection. Rising incidence linked to aging populations, chronic diseases, trauma, and post-disaster infections necessitates immediate medical attention, driving market growth. Rapid diagnostics, advanced imaging, and aggressive combination therapy are key market trends that aim to improve early detection and survival rates. However, delayed diagnosis, high treatment costs, and low disease awareness remain significant barriers. Despite these challenges, opportunities are emerging due to advancements in rapid point-of-care diagnostics, novel antimicrobial agents, and improved critical care protocols, allowing for earlier intervention and better patient outcomes in high-risk clinical settings.

Necrotizing Fasciitis Market- Market Dynamics

Rising Healthcare Expenditure Driving Market Growth

Rising healthcare expenditure is expected to significantly support the growth of the necrotizing fasciitis market in the coming years. Healthcare expenditure encompasses total spending by governments, private insurers, employers, and individuals on medical services, treatments, pharmaceuticals, and related healthcare activities. Increasing healthcare spending is largely driven by the rising burden of chronic diseases, which demand sustained medical care and advanced therapeutic interventions. Higher expenditure levels enhance the management of necrotizing fasciitis by improving access to early diagnostic technologies, innovative treatment options, and specialized critical care services.

For example, in June 2025, data released by the U.S. Centers for Medicare & Medicaid Services indicated that national health expenditures rose by 7.5% in 2023 to USD 4.9 trillion, or USD 14,570 per capita, accounting for 17.6% of GDP. Medicare spending increased by 8.1% to USD 1,029.8 billion, representing 21% of total national health expenditures. Consequently, expanding healthcare budgets are contributing to improved disease management and driving market growth.

Necrotizing Fasciitis Market- Segmentation Analysis:

The Global Necrotizing Fasciitis Market is segmented by Diagnosis, Symptoms, Drug, Type, End-Use, Treatment, Risk Factors, and Region.

The type II (monomicrobial) segment is expected to command a sizable portion of the global market. This increase can be attributed to the widespread infection with type II necrotizing fasciitis worldwide, as it is the most common type among types I and III and affects all age groups. Such a scenario is expected to prompt key players to increase the availability of antibiotic drugs, thereby driving segmental growth in the coming years. According to an article published on DermNet in August 2024, type II necrotizing fasciitis, also known as a flesh-eating disease, affects people of all ages, including those who are healthy.

Based on the Drug: The vancomycin segment is expected to account for a significant market share in the coming years. The segment's expansion can be attributed to the preference for vancomycin in combination with other drugs when methicillin-resistant Staphylococcus aureus (MRSA) is suspected. This is expected to increase the demand for vancomycin in the coming years. For example, the WHO Expert Committee on the Selection and Use of Essential Medicines stated in 2021 that vancomycin is effective against MRSA resistance when used in combination with other drugs.

Necrotizing Fasciitis Market- Geographical Insights

In 2025, North America will remain one of the key regions driving revenue and adoption in the Necrotizing Fasciitis (PPA) market, due to the increasing number of necrotizing fasciitis diagnoses is contributing to the region's growth. Such a scenario is driving demand for necrotizing fasciitis treatment, which is expected to accelerate market growth. For example, an article published by WebMD LLC in November 2023 states that approximately 700 to 1,150 cases of necrotizing fasciitis are diagnosed in the United States each year.

United States Necrotizing Fasciitis Market- Country Insights

The U.S. necrotizing fasciitis market benefits from advanced clinical research infrastructure and widespread access to modern diagnostic technologies, which support early identification and effective management of the disease. Additionally, leading healthcare providers and pharmaceutical companies, including Johnson & Johnson and Pfizer, are making substantial investments in the development of antimicrobial therapies and supportive care solutions. Government initiatives focused on strengthening infectious disease management protocols and increasing funding for rare disease research further reinforce market growth. For instance, NovaBay Pharmaceuticals is actively engaged in the wound-care segment, with its hypochlorous acid-based solution, NeutroPhase, being utilized for wound irrigation in severe infections, including necrotizing fasciitis, underscoring the country's strong emphasis on advanced treatment and care strategies.

Necrotizing Fasciitis Market- Competitive Landscape:

The competitive landscape of the necrotizing fasciitis market is shaped by healthcare providers, pharmaceutical firms, and medical device companies focused on early diagnosis, effective treatment, and improved patient outcomes. Competition is driven by advancements in rapid diagnostic solutions, broad-spectrum antibiotics, and supportive care therapies, as well as investments in research and development to address this rapidly progressing soft-tissue infection. Strategic collaborations between diagnostics developers and clinical institutions are increasing to enhance early detection and treatment protocols. Emerging technologies like AI-assisted imaging and molecular testing are also influencing market dynamics. Key players involved in addressing necrotizing fasciitis through therapeutic solutions and diagnostic support include Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, and Johnson & Johnson, each leveraging extensive R&D capabilities and global distribution networks to strengthen their market positions.

Recent Developments:

In June 2025, Evaxion A/S, a techbio company that specializes in AI-powered vaccines, has launched the EVX-B4 vaccine, which targets Group A Streptococcus (GAS), a bacterium that causes severe infections such as necrotizing fasciitis. The AI-driven program aims to improve preclinical development and speed up target discovery, contributing to Evaxion's growing vaccine pipeline for infectious diseases and cancer.

In October 2024, Florida health authorities reported a notable increase in cases of Vibrio vulnificus, the bacterium associated with severe "flesh-eating" infections, following Hurricane Helene. Data from the Florida Department of Health indicated an unusual surge across multiple counties, including Citrus, Hernando, and Sarasota. As of the reporting period, 74 cases had been recorded statewide, compared with 46 cases in 2023, resulting in 13 fatalities. This rise highlights the heightened public health risks linked to post-hurricane environmental conditions.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NECROTIZING FASCIITIS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Astellas Pharma
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Grifols SA
  • Takeda Pharmaceutical Company Ltd
  • AbbVie Inc.
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Roche Holding AG
  • Boehringer Ingelheim GmbH
  • Cipla Limited
  • Bayer AG
  • Amgen, Inc.
  • Others

GLOBAL NECROTIZING FASCIITIS MARKET, BY DIAGNOSIS- MARKET ANALYSIS, 2019 - 2032

  • Laboratory Tests
  • CT-Scan
  • Frozen Section Biopsy
  • MRI
  • Ultrasound

GLOBAL NECROTIZING FASCIITIS MARKET, BY SYMPTOMS- MARKET ANALYSIS, 2019 - 2032

  • Gangrene
  • Fever
  • Severe Drop in Blood Pressure
  • Nausea
  • Unconsciousness
  • Blisters
  • Others

GLOBAL NECROTIZING FASCIITIS MARKET, BY DRUG- MARKET ANALYSIS, 2019 - 2032

  • Imipenem
  • Metronidazole
  • Vancomycin
  • Piperacillin
  • Others

GLOBAL NECROTIZING FASCIITIS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Type I (Polymicrobial)
  • Type III (Gas gangrene / clostridial myonecrosis)
  • Type II (Monomicrobial)

GLOBAL NECROTIZING FASCIITIS MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032

  • Surgical Centers
  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Others

GLOBAL NECROTIZING FASCIITIS MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • MRSA-coverage add-ons
  • Empiric broad-spectrum antibacterials
  • Immunotherapies
  • Pathogen-targeted antibacterial regimens
  • Antitoxin adjunct for invasive GAS
  • Antifungals for necrotizing fungal infections

GLOBAL NECROTIZING FASCIITIS MARKET, BY RISK FACTORS- MARKET ANALYSIS, 2019 - 2032

  • Alcoholism
  • Diabetes
  • Peripheral Vascular Disease
  • Cancer
  • Obesity
  • Intravenous Drug Use

GLOBAL NECROTIZING FASCIITIS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Necrotizing Fasciitis Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Necrotizing Fasciitis Market Snippet by Diagnosis
    • 2.1.2. Necrotizing Fasciitis Market Snippet by Symptoms
    • 2.1.3. Necrotizing Fasciitis Market Snippet by Drug
    • 2.1.4. Necrotizing Fasciitis Market Snippet by Type
    • 2.1.5. Necrotizing Fasciitis Market Snippet by End-Use
    • 2.1.6. Necrotizing Fasciitis Market Snippet by Treatment
    • 2.1.7. Necrotizing Fasciitis Market Snippet by Risk Factors
    • 2.1.8. Necrotizing Fasciitis Market Snippet by Country
    • 2.1.9. Necrotizing Fasciitis Market Snippet by Region
  • 2.2. Competitive Insights

3. Necrotizing Fasciitis Key Market Trends

  • 3.1. Necrotizing Fasciitis Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Necrotizing Fasciitis Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Necrotizing Fasciitis Market Opportunities
  • 3.4. Necrotizing Fasciitis Market Future Trends

4. Necrotizing Fasciitis Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Necrotizing Fasciitis Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Necrotizing Fasciitis Market Landscape

  • 6.1. Necrotizing Fasciitis Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Necrotizing Fasciitis Market - By Diagnosis

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Diagnosis, 2024 & 2032 (%)
    • 7.1.2. Laboratory Tests
    • 7.1.3. CT-Scan
    • 7.1.4. Frozen Section Biopsy
    • 7.1.5. MRI
    • 7.1.6. Ultrasound

8. Necrotizing Fasciitis Market - By Symptoms

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Symptoms, 2024 & 2032 (%)
    • 8.1.2. Gangrene
    • 8.1.3. Fever
    • 8.1.4. Severe Drop in Blood Pressure
    • 8.1.5. Nausea
    • 8.1.6. Unconsciousness
    • 8.1.7. Blisters
    • 8.1.8. Others

9. Necrotizing Fasciitis Market - By Drug

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug, 2024 & 2032 (%)
    • 9.1.2. Imipenem
    • 9.1.3. Metronidazole
    • 9.1.4. Vancomycin
    • 9.1.5. Piperacillin
    • 9.1.6. Others

10. Necrotizing Fasciitis Market - By Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 10.1.2. Type I (Polymicrobial)
    • 10.1.3. Type III (Gas gangrene / clostridial myonecrosis)
    • 10.1.4. Type II (Monomicrobial)

11. Necrotizing Fasciitis Market - By End-Use

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End-Use, 2024 & 2032 (%)
    • 11.1.2. Surgical Centers
    • 11.1.3. Hospitals
    • 11.1.4. Clinics
    • 11.1.5. Diagnostic Centers
    • 11.1.6. Others

12. Necrotizing Fasciitis Market - By Treatment

  • 12.1. Overview
    • 12.1.1. Segment Share Analysis, By Treatment, 2024 & 2032 (%)
    • 12.1.2. MRSA-coverage add-ons
    • 12.1.3. Empiric broad-spectrum antibacterials
    • 12.1.4. Immunotherapies
    • 12.1.5. Pathogen-targeted antibacterial regimens
    • 12.1.6. Antitoxin adjunct for invasive GAS
    • 12.1.7. Antifungals for necrotizing fungal infections

13. Necrotizing Fasciitis Market - By Risk Factors

  • 13.1. Overview
    • 13.1.1. Segment Share Analysis, By Risk Factors, 2024 & 2032 (%)
    • 13.1.2. Alcoholism
    • 13.1.3. Diabetes
    • 13.1.4. Peripheral Vascular Disease
    • 13.1.5. Cancer
    • 13.1.6. Obesity
    • 13.1.7. Intravenous Drug Use

14. Necrotizing Fasciitis Market- By Geography

  • 14.1. Introduction
    • 14.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 14.2. North America
    • 14.2.1. Overview
    • 14.2.2. Necrotizing Fasciitis Key Manufacturers in North America
    • 14.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.2.4. North America Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 14.2.5. North America Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
    • 14.2.6. North America Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.2.7. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.2.8. North America Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.2.9. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 14.2.10. North America Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.2.11. U.S.
      • 14.2.11.1. Overview
      • 14.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.11.3. U.S. Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.2.11.4. U.S. Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.2.11.5. U.S. Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.2.11.6. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.2.11.7. U.S. Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.2.11.8. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.2.11.9. U.S. Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.2.12. Canada
      • 14.2.12.1. Overview
      • 14.2.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.12.3. Canada Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.2.12.4. Canada Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.2.12.5. Canada Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.2.12.6. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.2.12.7. Canada Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.2.12.8. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.2.12.9. Canada Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
  • 14.3. Europe
    • 14.3.1. Overview
    • 14.3.2. Necrotizing Fasciitis Key Manufacturers in Europe
    • 14.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.3.4. Europe Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 14.3.5. Europe Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
    • 14.3.6. Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.3.7. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.3.8. Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.3.9. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 14.3.10. Europe Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.3.11. Germany
      • 14.3.11.1. Overview
      • 14.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.11.3. Germany Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.3.11.4. Germany Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.3.11.5. Germany Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.11.6. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.11.7. Germany Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.11.8. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.3.11.9. Germany Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.3.12. UK
      • 14.3.12.1. Overview
      • 14.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.12.3. UK Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.3.12.4. UK Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.3.12.5. UK Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.12.6. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.12.7. UK Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.12.8. UK Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.3.12.9. UK Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.3.13. France
      • 14.3.13.1. Overview
      • 14.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.13.3. France Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.3.13.4. France Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.3.13.5. France Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.13.6. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.13.7. France Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.13.8. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.3.13.9. France Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.3.14. Italy
      • 14.3.14.1. Overview
      • 14.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.14.3. Italy Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.3.14.4. Italy Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.3.14.5. Italy Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.14.6. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.14.7. Italy Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.14.8. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.3.14.9. Italy Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.3.15. Spain
      • 14.3.15.1. Overview
      • 14.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.15.3. Spain Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.3.15.4. Spain Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.3.15.5. Spain Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.15.6. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.15.7. Spain Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.15.8. Spain Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.3.15.9. Spain Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.3.16. The Netherlands
      • 14.3.16.1. Overview
      • 14.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.16.3. The Netherlands Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.3.16.4. The Netherlands Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.3.16.5. The Netherlands Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.16.6. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.16.7. The Netherlands Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.16.8. The Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.3.16.9. The Netherlands Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.3.17. Sweden
      • 14.3.17.1. Overview
      • 14.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.17.3. Sweden Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.3.17.4. Sweden Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.3.17.5. Sweden Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.17.6. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.17.7. Sweden Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.17.8. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.3.17.9. Sweden Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.3.18. Russia
      • 14.3.18.1. Overview
      • 14.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.18.3. Russia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.3.18.4. Russia Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.3.18.5. Russia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.18.6. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.18.7. Russia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.18.8. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.3.18.9. Russia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.3.19. Poland
      • 14.3.19.1. Overview
      • 14.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.19.3. Poland Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.3.19.4. Poland Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.3.19.5. Poland Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.19.6. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.19.7. Poland Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.19.8. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.3.19.9. Poland Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.3.20. Rest of Europe
      • 14.3.20.1. Overview
      • 14.3.20.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.20.3. Rest of the Europe Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.3.20.4. Rest of the Europe Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.3.20.5. Rest of the Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.20.6. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.20.7. Rest of the Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.20.8. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.3.20.9. Rest of the Europe Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
  • 14.4. Asia Pacific (APAC)
    • 14.4.1. Overview
    • 14.4.2. Necrotizing Fasciitis Key Manufacturers in Asia Pacific
    • 14.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.4.4. APAC Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 14.4.5. APAC Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
    • 14.4.6. APAC Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.4.7. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.4.8. APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.4.9. APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 14.4.10. APAC Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.4.11. China
      • 14.4.11.1. Overview
      • 14.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.11.3. China Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.4.11.4. China Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.4.11.5. China Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.11.6. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.11.7. China Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.11.8. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.4.11.9. China Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.4.12. India
      • 14.4.12.1. Overview
      • 14.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.12.3. India Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.4.12.4. India Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.4.12.5. India Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.12.6. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.12.7. India Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.12.8. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.4.12.9. India Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.4.13. Japan
      • 14.4.13.1. Overview
      • 14.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.13.3. Japan Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.4.13.4. Japan Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.4.13.5. Japan Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.13.6. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.13.7. Japan Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.13.8. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.4.13.9. Japan Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.4.14. South Korea
      • 14.4.14.1. Overview
      • 14.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.14.3. South Korea Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.4.14.4. South Korea Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.4.14.5. South Korea Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.14.6. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.14.7. South Korea Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.14.8. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.4.14.9. South Korea Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.4.15. Australia
      • 14.4.15.1. Overview
      • 14.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.15.3. Australia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.4.15.4. Australia Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.4.15.5. Australia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.15.6. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.15.7. Australia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.15.8. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.4.15.9. Australia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.4.16. Indonesia
      • 14.4.16.1. Overview
      • 14.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.16.3. Indonesia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.4.16.4. Indonesia Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.4.16.5. Indonesia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.16.6. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.16.7. Indonesia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.16.8. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.4.16.9. Indonesia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.4.17. Thailand
      • 14.4.17.1. Overview
      • 14.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.17.3. Thailand Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.4.17.4. Thailand Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.4.17.5. Thailand Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.17.6. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.17.7. Thailand Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.17.8. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.4.17.9. Thailand Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.4.18. Philippines
      • 14.4.18.1. Overview
      • 14.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.18.3. Philippines Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.4.18.4. Philippines Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.4.18.5. Philippines Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.18.6. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.18.7. Philippines Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.18.8. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.4.18.9. Philippines Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.4.19. Rest of APAC
      • 14.4.19.1. Overview
      • 14.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.19.3. Rest of APAC Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.4.19.4. Rest of APAC Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.4.19.5. Rest of APAC Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.19.6. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.19.7. Rest of APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.19.8. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.4.19.9. Rest of APAC Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
  • 14.5. Latin America (LATAM)
    • 14.5.1. Overview
    • 14.5.2. Necrotizing Fasciitis Key Manufacturers in Latin America
    • 14.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.5.4. LATAM Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 14.5.5. LATAM Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
    • 14.5.6. LATAM Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.5.7. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.5.8. LATAM Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.5.9. LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 14.5.10. LATAM Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.5.11. Brazil
      • 14.5.11.1. Overview
      • 14.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.11.3. Brazil Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.5.11.4. Brazil Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.5.11.5. Brazil Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.11.6. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.11.7. Brazil Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.11.8. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.5.11.9. Brazil Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.5.12. Mexico
      • 14.5.12.1. Overview
      • 14.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.12.3. Mexico Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.5.12.4. Mexico Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.5.12.5. Mexico Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.12.6. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.12.7. Mexico Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.12.8. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.5.12.9. Mexico Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.5.13. Argentina
      • 14.5.13.1. Overview
      • 14.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.13.3. Argentina Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.5.13.4. Argentina Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.5.13.5. Argentina Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.13.6. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.13.7. Argentina Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.13.8. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.5.13.9. Argentina Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.5.14. Colombia
      • 14.5.14.1. Overview
      • 14.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.14.3. Colombia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.5.14.4. Colombia Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.5.14.5. Colombia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.14.6. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.14.7. Colombia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.14.8. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.5.14.9. Colombia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.5.15. Rest of LATAM
      • 14.5.15.1. Overview
      • 14.5.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.15.3. Rest of LATAM Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.5.15.4. Rest of LATAM Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.5.15.5. Rest of LATAM Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.15.6. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.15.7. Rest of LATAM Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.15.8. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.5.15.9. Rest of LATAM Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
  • 14.6. Middle East and Africa
    • 14.6.1. Overview
    • 14.6.2. Necrotizing Fasciitis Key Manufacturers in Middle East and Africa
    • 14.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.6.4. Middle East and Africa Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 14.6.5. Middle East and Africa Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
    • 14.6.6. Middle East and Africa Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.6.7. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.6.8. Middle East and Africa Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.6.9. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 14.6.10. Middle East and Africa Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.6.11. Saudi Arabia
      • 14.6.11.1. Overview
      • 14.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.11.3. Saudi Arabia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.6.11.4. Saudi Arabia Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.6.11.5. Saudi Arabia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.11.6. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.11.7. Saudi Arabia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.11.8. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.6.11.9. Saudi Arabia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.6.12. United Arab Emirates
      • 14.6.12.1. Overview
      • 14.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.12.3. United Arab Emirates Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.6.12.4. United Arab Emirates Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.6.12.5. United Arab Emirates Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.12.6. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.12.7. United Arab Emirates Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.12.8. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.6.12.9. United Arab Emirates Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.6.13. Israel
      • 14.6.13.1. Overview
      • 14.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.13.3. Israel Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.6.13.4. Israel Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.6.13.5. Israel Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.13.6. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.13.7. Israel Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.13.8. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.6.13.9. Israel Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.6.14. Turkey
      • 14.6.14.1. Overview
      • 14.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.14.3. Turkey Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.6.14.4. Turkey Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.6.14.5. Turkey Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.14.6. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.14.7. Turkey Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.14.8. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.6.14.9. Turkey Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.6.15. Algeria
      • 14.6.15.1. Overview
      • 14.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.15.3. Algeria Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.6.15.4. Algeria Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.6.15.5. Algeria Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.15.6. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.15.7. Algeria Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.15.8. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.6.15.9. Algeria Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.6.16. Egypt
      • 14.6.16.1. Overview
      • 14.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.16.3. Egypt Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.6.16.4. Egypt Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.6.16.5. Egypt Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.16.6. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.16.7. Egypt Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.16.8. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.6.16.9. Egypt Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 14.6.17. Rest of MEA
      • 14.6.17.1. Overview
      • 14.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.17.3. Rest of MEA Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 14.6.17.4. Rest of MEA Market Size and Forecast, By Symptoms, 2019 - 2032 (US$ Million)
      • 14.6.17.5. Rest of MEA Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.17.6. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.17.7. Rest of MEA Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.17.8. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 14.6.17.9. Rest of MEA Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)

15. Key Vendor Analysis- Necrotizing Fasciitis Industry

  • 15.1. Competitive Benchmarking
    • 15.1.1. Competitive Dashboard
    • 15.1.2. Competitive Positioning
  • 15.2. Company Profiles
    • 15.2.1. Astellas Pharma
    • 15.2.2. Johnson & Johnson
    • 15.2.3. Teva Pharmaceutical Industries Ltd.
    • 15.2.4. GlaxoSmithKline plc
    • 15.2.5. Pfizer, Inc.
    • 15.2.6. Eli Lilly and Company
    • 15.2.7. Grifols SA
    • 15.2.8. Takeda Pharmaceutical Company Ltd
    • 15.2.9. AbbVie Inc.
    • 15.2.10. Sanofi
    • 15.2.11. F. Hoffmann-La Roche Ltd
    • 15.2.12. Roche Holding AG
    • 15.2.13. Boehringer Ingelheim GmbH
    • 15.2.14. Cipla Limited
    • 15.2.15. Bayer AG
    • 15.2.16. Amgen, Inc.
    • 15.2.17. Others

16. 360 Degree Analyst View

17. Appendix

  • 17.1. Research Methodology
  • 17.2. References
  • 17.3. Abbreviations
  • 17.4. Disclaimer
  • 17.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제